Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Time to Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $11.22, but opened at $11.80. Santen Pharmaceutical shares last traded at $11.72, with a volume of 15,270 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The company has a market capitalization of $3.80 billion and a price-to-earnings ratio of 0.10. The business has a 50 day moving average price of $11.31 and a 200-day moving average price of $10.91.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.